F901318 Single Ascending Dose Study in Healthy Male Volunteers

F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.

 

Condition Intervention Phase
Invasive Aspergillosis Drug: F901318
Drug: Placebo
Phase 1

 

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects

Antifungal name: 

Date of article/Start date of trial: 

Tuesday, May 13, 2014

Trial phase: 

Phase 1

ClinicalTrials.gov ID: 

NCT02142153

Trial status: 

Completed
New antifungal drugs